BR112020004903A2 - uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica - Google Patents

uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica Download PDF

Info

Publication number
BR112020004903A2
BR112020004903A2 BR112020004903-4A BR112020004903A BR112020004903A2 BR 112020004903 A2 BR112020004903 A2 BR 112020004903A2 BR 112020004903 A BR112020004903 A BR 112020004903A BR 112020004903 A2 BR112020004903 A2 BR 112020004903A2
Authority
BR
Brazil
Prior art keywords
individual
administration
gevoquizumab
canaquinumab
fact
Prior art date
Application number
BR112020004903-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Shephard Mpofu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112020004903A2 publication Critical patent/BR112020004903A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR112020004903-4A 2017-09-13 2018-09-11 uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica BR112020004903A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762557929P 2017-09-13 2017-09-13
US62/557,929 2017-09-13
US201862647088P 2018-03-23 2018-03-23
US62/647,088 2018-03-23
PCT/IB2018/056928 WO2019053591A1 (en) 2017-09-13 2018-09-11 USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS

Publications (1)

Publication Number Publication Date
BR112020004903A2 true BR112020004903A2 (pt) 2020-09-15

Family

ID=63708416

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004903-4A BR112020004903A2 (pt) 2017-09-13 2018-09-11 uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica

Country Status (14)

Country Link
US (3) US20200207848A1 (enExample)
EP (1) EP3717006A1 (enExample)
JP (1) JP2020533353A (enExample)
KR (1) KR20200052331A (enExample)
CN (1) CN111315412A (enExample)
AU (1) AU2018333106A1 (enExample)
BR (1) BR112020004903A2 (enExample)
CA (1) CA3075711A1 (enExample)
CL (1) CL2020000631A1 (enExample)
IL (1) IL273204A (enExample)
MX (1) MX2020002813A (enExample)
RU (1) RU2020113234A (enExample)
TW (1) TW201920269A (enExample)
WO (1) WO2019053591A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
MX2016014731A (es) * 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
KR101695848B1 (ko) * 2015-03-03 2017-01-13 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
TW201920269A (zh) 2019-06-01
WO2019053591A1 (en) 2019-03-21
JP2020533353A (ja) 2020-11-19
MX2020002813A (es) 2020-07-21
AU2018333106A1 (en) 2020-04-02
US20200207848A1 (en) 2020-07-02
CA3075711A1 (en) 2019-03-21
EP3717006A1 (en) 2020-10-07
IL273204A (en) 2020-04-30
US20230235043A1 (en) 2023-07-27
US20210309736A1 (en) 2021-10-07
RU2020113234A3 (enExample) 2022-04-28
CN111315412A (zh) 2020-06-19
CL2020000631A1 (es) 2020-09-11
RU2020113234A (ru) 2021-10-13
KR20200052331A (ko) 2020-05-14

Similar Documents

Publication Publication Date Title
Sinha et al. Nephrotic syndrome
CN104244956B (zh) 使用环糊精的方法
Peilin et al. Directed elimination of senescent cells attenuates development of osteoarthritis by inhibition of c-IAP and XIAP
Zhou et al. CSF1/CSF1R-mediated crosstalk between choroidal vascular endothelial cells and macrophages promotes choroidal neovascularization
Liao et al. 2-Methoxyestradiol protects against lung ischemia/reperfusion injury by upregulating annexin A1 protein expression
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
Zhou et al. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice
Gesslein et al. Tumor necrosis factor and its receptors in the neuroretina and retinal vasculature after ischemia-reperfusion injury in the pig retina
Hiraumi et al. Granulocyte colony-stimulating factor protects cardiac mitochondria in the early phase of cardiac injury
US10758551B2 (en) Methods and compositions for treating pancreatitis
US20230235043A1 (en) Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
US20220220206A1 (en) Treating chronic liver disease
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
CN111671749A (zh) 双香豆素在制备HBx蛋白稳定性抑制剂中的用途
WO2022105870A1 (en) Methods of treating systemic lupus erythematosus using btk inhibitors
Li et al. The pyranocoumarin-enriched extract from the leaves of Calophyllum membranaceum alleviates LPS-induced acute lung injury in mice by inhibiting the TLR4/MD2 interaction
Jing et al. Therapeutic effects of salidroside vs pyrrolidine dithiocarbamate against severe acute pancreatitis in rats
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
WO2019048898A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
WO2026026911A1 (zh) 一种二肽衍生物的应用
TW202313028A (zh) 使用s-羥氯喹的抗磷脂質症候群之治療
WO2023205249A1 (en) Nicotine and nicotinic agonist compositions for the prevention and treatment of pancreatitis and methods of using same
HK40032085A (en) Method of using cyclodextrin
Zhang et al. Di Wang 1, 5 Kai Jin 2 Chang Ying 1, 5 Bin Li 2
HK40012462B (en) Treatment of nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VER PARECER.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing

Free format text: O PEDIDO DE EXAME PARA ESSE PEDIDO, DE ACORDO COM O ART. 33 DA LPI; PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020; PORTARIA INPI PR NO 179 DE 11/05/2020 E PORTARIA INPI NO 334 DE 24/09/2020, POSSUIA PRAZO PARA SER REQUERIDO ATE 11/09/2021. HOUVE TEMPESTIVAMENTE O PAGAMENTO A MENOR DO PEDIDO DE EXAME, SENDO PUBLICADO UMA EXIGENCIA 6.7 DE COMPLEMENTACAO PUBLICADA NA RPI 2721 DE 28/02/2023. NAO APRESENTOU MANIFESTACAO A EXIGENCIA 6.7 DE COMPLEMENTACAO DO PEDIDO DE EXAME, QUE POSSUIA PRAZO ATE 30/05/2023. DESSA FORMA O PEDIDO SERA ARQUIVADO. PARA QUE O MESMO POSSA SER APROVEITADO E NECESSARIO: 1) EFETUAR O PAGAMENTO, EM UM PRA

B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]

Free format text: O PEDIDO DE EXAME PARA ESSE PEDIDO, DE ACORDO COM O ART. 33 DA LPI, POSSUIA PRAZO PARA SER REQUERIDO ATE 11/09/2021. HOUVE TEMPESTIVAMENTE O PAGAMENTO A MENOR DO PEDIDO DE EXAME, SENDO PUBLICADO UMA EXIGENCIA 6.7 DE COMPLEMENTACAO PUBLICADA NA RPI 2721 DE 28/02/2023. NAO APRESENTOU MANIFESTACAO A EXIGENCIA 6.7 DE COMPLEMENTACAO DO PEDIDO DE EXAME, QUE POSSUIA PRAZO ATE 31/05/2023. NA RPI 2737 DE 20/06/2023 FOI PUBLICADO O DESPACHO 11.1 DE ARQUIVAMENTO DE ACORDO COM O ART. 33 DA LPI, SENDO SOLICITADO O PAGAMENTO DA SOLICITACAO DE DESARQUIVAMENTO, COMPLEMENTACAO DO PEDIDO DE EXAME E PETICIONAMENTO APRESENTANDO A GRU DE COMPLEMENTACAO. NAO HOUVE MANIFESTACAO AO DESPACHO 11.1 DE ARQUIVAMENTO, QU